Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A drug-repurposing screening identifies TgGSK3 as a novel drug-target for Apicomplexan parasites.

ABSTRACT: A drug-repurposing screening identifies TgGSK3 as a novel drug-target for Apicomplexan parasites.

PROVIDER: PRJNA1208950 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31951400_1.fastq.gz	Fastqsanger.gz
	SRR31951400_2.fastq.gz	Fastqsanger.gz
	SRR31951392_1.fastq.gz	Fastqsanger.gz
	SRR31951392_2.fastq.gz	Fastqsanger.gz
	SRR31951393_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

A drug-repurposing screening identifies TgGSK3 as a novel drug-target for Apicomplexan parasites.

Project description:To shed light on the parasiticidal mechanisms of L2090314, we have adapted a workflow which combines a forward genetic approach based on transcriptome sequencing, computational mutation discovery, and CRISPR/Cas9 genome editing in Toxoplasma gondii. Drug-resistant parasites were generated by chemical random mutagenesis. Multiple independent resistant lines were isolated. Single nucleotide variations (SNVs) were identified based on NGS transcriptomic analysis. By focusing on mutations present in coding sequences, we identified a single gene, TgGSK3, that harbored SNVs leading to amino acid substitutions in the 8 drug-resistant lines obtained that were not present in the parental strain. Finally, using CRISPR/Cas9 genome editing we confirmed that the mutations identified confer resistance against LY2090314.

2025-01-20 | GSE286338 | GEO

Drug screening in Drosophila for repurposing in neuropsychiatry

Project description:Drug screening in Drosophila for repurposing in neuropsychiatry

| PRJNA596785 | ENA

Drug repurposing in rare diseases: an integrative study of drug screening and transcriptomic analysis in nephropathic cystinosis

Project description:Drug repurposing in rare diseases: an integrative study of drug screening and transcriptomic analysis in nephropathic cystinosis

| PRJNA766553 | ENA

Discovery of kinetochore and spindle assembly checkpoint proteins in apicomplexan parasites

Project description:Kinetochores are multiprotein assemblies that bind chromosomes to the spindle during mitosis. Despite conserved roles, repertoires of kinetochore proteins vary greatly across eukaryotes. In particular, most known components are not clearly detected in a group of parasites known as the Apicomplexa. Furthermore, flexibility in scale of amplification and an apparent incapability to delay cell cycle progression in response to spindle integrity has coined an idea these parasites divide in the absence of spindle checkpoints. In this study, we reunite divergent apicomplexan kinetochore components to a common eukaryotic set and additionally identify 9 kinetochore proteins that share little homology to known proteins. AKiTs are essential for chromosome segregation and show modes of division parallel to eukaryotic metaphase to anaphase transition and spindle assembly checkpoint signaling. These findings suggest conserved spindle assembly checkpoint signaling maintains fidelity during chromosome segregation in apicomplexan parasites.

2023-03-11 | PXD028595 | Pride

Machine Learning Identifies Candidates for Drug Repurposing in Alzheimer's Disease

Project description:Clinical trials of novel therapeutics for Alzheimer's Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. In this study, we profile 80 FDA-approved and clinically tested drugs in neural cell cultures, with the goal of producing a ranked list of possible repurposing candidates.

2021-01-14 | GSE164788 | GEO

20230905 ReFRAME drug repurposing collection DDA spectra

Project description:DDA analysis of 14,000 drugs in the ReFRAME drug repurposing collection. Positive and negative ionizations.

| MSV000092822 | MassIVE

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [Tissue_RNA-seq]

Project description:we present a novel path to drug repurposing to identify new immunotherapies for ASCVD. The integration of time of-flight mass cytometry (CyTOF) and RNA-sequencing identified unique inflammatory signatures in peripheral blood mononuclear cells (PBMCs) stimulated with ASCVD plasma. By comparing these inflammatory signatures to large-scale gene expression data from the LINCS L1000 dataset, we identified drugs that could reverse this inflammatory response. In conclusion, a systems immunology-driven drug repurposing with pre- clinical validation strategy can aid the development of new cardiovascular immunotherapies.

2023-04-23 | GSE230216 | GEO

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [DRUG_RNA-seq]

2023-04-23 | GSE230215 | GEO

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [RNA-seq_PBMC]

2023-04-23 | GSE230214 | GEO

Leishmania parasites exchange drug-resistance genes through extracellular vesicles

Project description:Leishmania are ancient eukaryotes that have retained the ability to produce extracellular vesicles (EVs) through evolution. Until date, it was unclear if different DNA entities could be associated to Leishmania EVs, and whether these could constitute a novel mechanism of horizontal gene transfer (HGT). Herein, we investigated the DNA content of EVs derived from drug-resistant parasites, as well as the potential of EVs as shuttles for DNA transfer. Next-generation sequencing, and PCR assays confirmed the enrichment of amplicons carrying drug-resistance genes associated to EVs. Transfer assays of drug-resistant EVs highlighted a significant impact in the phenotype of recipient parasites induced by the expression of the transferred DNA. Recipient parasites displayed an enhanced growth and better control of oxidative stress. We provide the first evidence that eukaryotic EVs function as efficient mediators in HGT, thereby facilitating the transmission of drug-resistance genes and increasing the fitness of cells when encountering stressful environments.

2022-07-19 | GSE200222 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data